Decoy Therapeutics Regains Nasdaq Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Decoy Therapeutics announces that on March 31, the company received notification from the Nasdaq Stock Market that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market. Nasdaq further notified the company that it will be subject to a Mandatory Panel Monitor for a period of one year from March 31. If, within that one-year monitoring period, the Listing Qualifications Staff finds the company out of compliance with the Minimum Bid Price Requirement that was the subject of the exception, the Staff will issue a delisting determination letter and the company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DCOY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DCOY
About DCOY
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Decoy Therapeutics Initiates Clinical Studies for New Antiviral Category
- Strategic Collaboration: Decoy Therapeutics has signed an agreement with hVIVO to support its Designable Multi-Antiviral (D-MAV) candidates in Phase 1 and Phase 2a clinical studies, marking a significant advancement in the antiviral sector.
- Clinical Development Support: hVIVO will provide comprehensive support including translational modeling, regulatory strategy, and clinical development planning, ensuring smooth preparation for D-MAV candidates' clinical trials, thereby accelerating the drug's path to market.
- Innovative Platform Utilization: Decoy's IMP³ACT™ platform integrates AI-driven peptide design with rapid synthesis technology, enabling D-MAV candidates to enter clinical trials more swiftly, enhancing the ability to respond to emerging viral threats.
- Market Potential Outlook: Decoy plans to leverage the outputs from its collaboration with hVIVO to facilitate the registration of its D-MAV candidates in the US and Europe, aiming to address multiple respiratory viruses with a single adaptable therapeutic approach to meet global health needs.
See More
Decoy Therapeutics Nominates New Director
- New Board Nomination: Decoy Therapeutics has nominated Patricia Gauthier as a Class II director, with a vote scheduled for the July 14, 2026 Annual Meeting, aiming to leverage her extensive experience in biomanufacturing and national health security partnerships to advance D-MAV programs into clinical stages.
- Extensive Industry Background: Since 2025, Gauthier has served as Senior Vice President at Moderna, overseeing strategy and operations across Australia, Canada, and the UK, successfully delivering over 50 million COVID-19 vaccine doses and securing a landmark biomanufacturing partnership with the Canadian government, showcasing her leadership in the vaccine sector.
- Antiviral Drug Innovation: Gauthier emphasizes that Decoy's D-MAV approach offers a robust model for adaptable antiviral medicines by targeting shared viral mechanisms, potentially expanding the possibilities in viral prevention and treatment, which aligns with the global demand for new antiviral solutions.
- Strategic Company Development: This nomination not only recognizes Gauthier's capabilities but also reflects Decoy Therapeutics' strategic intent to enhance its influence in the global health market, aiming to address future viral threats through its innovative antiviral drug pipeline.
See More
Decoy Therapeutics Partners with hVIVO for D-MAV Clinical Development
- Strategic Partnership: Decoy Therapeutics has entered into a strategic development agreement with European pharmaceutical service partner hVIVO plc to advance its lead D-MAV candidate into Phase 1 first-in-human and Phase 2a proof-of-concept studies, marking a significant step in addressing respiratory viral infections.
- Regulatory Support: Under the agreement, hVIVO will provide Decoy with regulatory strategy, translational modeling, scientific advice preparation, CMC consulting, and non-clinical development support, ensuring smooth clinical trial submissions in Europe and the UK, thereby accelerating the drug's market entry.
- Clinical Development Planning: Decoy intends to leverage the data generated to update its clinical development strategy, including Phase 1 dose selection, translational pharmacology planning, and challenge study design considerations, ensuring effective progression of its D-MAV programs.
- Long-term Goals: This collaboration not only supports early clinical execution and regulatory planning but also lays the groundwork for future IND/CTA filings with the FDA, demonstrating Decoy's strategic positioning for the global market.
See More
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston
- Leadership Roundtable: Chief Business Officer Peter Marschel will lead a 60-minute roundtable at the Oligonucleotide & Peptides HubXchange on April 30, discussing key challenges in computational design of peptide therapeutics, aiming to drive innovation in peptide drug design and enhance the company's competitiveness in the antiviral space.
- New Strategic Partnership: Decoy has formed a strategic partnership with Quantorito to deploy a Google Cloud-native, AI-driven peptide design platform, significantly shortening the cycle from peptide design to D-MAV candidates, showcasing how computational work can accelerate the shift from ligand reengineering to de novo design, further advancing the company's technological progress.
- Case Study Presentation: Chief Scientific Officer Barbara Hibner and Chief Technology Officer Michael Lipp will co-present a case study on
See More
Decoy Therapeutics Initiates Clinical Studies for New Antiviral Category
- Strategic Collaboration: Decoy Therapeutics has signed an agreement with hVIVO to support its Designable Multi-Antiviral (D-MAV) candidates in Phase 1 and Phase 2a clinical studies, marking a significant advancement in the antiviral sector.
- Clinical Development Support: hVIVO will provide comprehensive support including translational modeling, regulatory strategy, and clinical development planning, ensuring smooth preparation for D-MAV candidates' clinical trials, thereby accelerating the drug's path to market.
- Innovative Platform Utilization: Decoy's IMP³ACT™ platform integrates AI-driven peptide design with rapid synthesis technology, enabling D-MAV candidates to enter clinical trials more swiftly, enhancing the ability to respond to emerging viral threats.
- Market Potential Outlook: Decoy plans to leverage the outputs from its collaboration with hVIVO to facilitate the registration of its D-MAV candidates in the US and Europe, aiming to address multiple respiratory viruses with a single adaptable therapeutic approach to meet global health needs.
See More
Decoy Therapeutics Nominates New Director
- New Board Nomination: Decoy Therapeutics has nominated Patricia Gauthier as a Class II director, with a vote scheduled for the July 14, 2026 Annual Meeting, aiming to leverage her extensive experience in biomanufacturing and national health security partnerships to advance D-MAV programs into clinical stages.
- Extensive Industry Background: Since 2025, Gauthier has served as Senior Vice President at Moderna, overseeing strategy and operations across Australia, Canada, and the UK, successfully delivering over 50 million COVID-19 vaccine doses and securing a landmark biomanufacturing partnership with the Canadian government, showcasing her leadership in the vaccine sector.
- Antiviral Drug Innovation: Gauthier emphasizes that Decoy's D-MAV approach offers a robust model for adaptable antiviral medicines by targeting shared viral mechanisms, potentially expanding the possibilities in viral prevention and treatment, which aligns with the global demand for new antiviral solutions.
- Strategic Company Development: This nomination not only recognizes Gauthier's capabilities but also reflects Decoy Therapeutics' strategic intent to enhance its influence in the global health market, aiming to address future viral threats through its innovative antiviral drug pipeline.
See More
Decoy Therapeutics Partners with hVIVO for D-MAV Clinical Development
- Strategic Partnership: Decoy Therapeutics has entered into a strategic development agreement with European pharmaceutical service partner hVIVO plc to advance its lead D-MAV candidate into Phase 1 first-in-human and Phase 2a proof-of-concept studies, marking a significant step in addressing respiratory viral infections.
- Regulatory Support: Under the agreement, hVIVO will provide Decoy with regulatory strategy, translational modeling, scientific advice preparation, CMC consulting, and non-clinical development support, ensuring smooth clinical trial submissions in Europe and the UK, thereby accelerating the drug's market entry.
- Clinical Development Planning: Decoy intends to leverage the data generated to update its clinical development strategy, including Phase 1 dose selection, translational pharmacology planning, and challenge study design considerations, ensuring effective progression of its D-MAV programs.
- Long-term Goals: This collaboration not only supports early clinical execution and regulatory planning but also lays the groundwork for future IND/CTA filings with the FDA, demonstrating Decoy's strategic positioning for the global market.
See More
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston
- Leadership Roundtable: Chief Business Officer Peter Marschel will lead a 60-minute roundtable at the Oligonucleotide & Peptides HubXchange on April 30, discussing key challenges in computational design of peptide therapeutics, aiming to drive innovation in peptide drug design and enhance the company's competitiveness in the antiviral space.
- New Strategic Partnership: Decoy has formed a strategic partnership with Quantorito to deploy a Google Cloud-native, AI-driven peptide design platform, significantly shortening the cycle from peptide design to D-MAV candidates, showcasing how computational work can accelerate the shift from ligand reengineering to de novo design, further advancing the company's technological progress.
- Case Study Presentation: Chief Scientific Officer Barbara Hibner and Chief Technology Officer Michael Lipp will co-present a case study on
See More
